Publications by authors named "Paul Delmar"

Claim this Profile
S
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
Randall J Bateman, Yan Li, Eric M McDade, Jorge J Llibre-Guerra, David B Clifford, Paul Delmar

Lancet Neurol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Japanese participant data from three gantenerumab trials in early Alzheimer's disease.
Takashi Asada, Angeliki Thanasopoulou, Paul Delmar, Jakub Wojtowicz, Janice Smith

Alzheimers Dement· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker treatment effects in two phase 3 trials of gantenerumab.
Tobias Bittner, Matteo Tonietto, Gregory Klein, Anton Belusov, Vittorio Illiano, Paul Delmar

Alzheimers Dement· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).
Mercè Boada, Anuja Neve, Bibha Das, Jakub Wojtowicz, Zhiyue Huang, Paul Delmar

J Alzheimers Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial.
Randall J Bateman, Yan Li, Eric M McDade, Jorge J Llibre-Guerra, David B Clifford, Paul Delmar

medRxiv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rejoinder to the letter: "Standard and reference-based conditional mean imputation: Regulators and trial statisticians be aware!".
Marcel Wolbers, Alessandro Noci, Paul Delmar, Sean Yiu, Jonathan W Bartlett

Pharm Stat· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Care partner-informed meaningful change thresholds for the Clinical Dementia Rating-Sum of Boxes for trials of early Alzheimer's disease.
Claire J Lansdall, Edmond Teng, Jerome Chague, Rohan Palanganda, Paul Delmar

Alzheimers Dement· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical considerations when estimating time-saving treatment effects in Alzheimer's disease clinical trials.
Guoqiao Wang, Gary Cutter, Neil P Oxtoby, Guogen Shan, Whedy Wang, Paul Delmar

Alzheimers Dement· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).
Anuja Neve, Bibha Das, Jakub Wojtowicz, Zhiyue Huang, Szofia Bullain, Paul Delmar

J Alzheimers Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease.
Guoqiao Wang, Yan Li, Chengjie Xiong, Tammie L S Benzinger, Brian A Gordon, Paul Delmar

Alzheimers Dement· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Randall J Bateman, Janice Smith, Michael C Donohue, Paul Delmar, Rachid Abbas

N Engl J Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing ARIA-E severity scales and effects of treatment management thresholds.
Gregory Klein, Marzia A Scelsi, Jerome Barakos, Jochen B Fiebach, Luc Bracoud, Paul Delmar

Alzheimers Dement (Amst)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard and reference-based conditional mean imputation.
Marcel Wolbers, Alessandro Noci, Paul Delmar, Craig Gower-Page, Sean Yiu

Pharm Stat· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Guoqiao Wang, Yan Li, Chengjie Xiong, Eric McDade, David B Clifford, Paul Delmar

Alzheimers Dement (Amst)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.
Roxana Aldea, Hans Peter Grimm, Ronald Gieschke, Carsten Hofmann, Dominik Lott, Paul Delmar

Alzheimers Dement (N Y)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease.
Guoqiao Wang, Lei Liu, Yan Li, Andrew J Aschenbrenner, Randall J Bateman, Paul Delmar

Alzheimers Dement (N Y)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Classification, Prediction, and Concordance of Cognitive and Functional Progression in Patients with Mild Cognitive Impairment in the United States: A Latent Class Analysis.
Julie Mouchet, Keith A Betts, Mihaela V Georgieva, Raluca Ionescu-Ittu, Lesley M Butler, Paul Delmar

J Alzheimers Dis· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Stephen Salloway, Martin Farlow, Eric McDade, David B Clifford, Guoqiao Wang, Paul Delmar

Nat Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach.
Michael C Donohue, Fabian Model, Paul Delmar, Nicola Volye, Hong Liu-Seifert

Alzheimers Dement· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
Gregory Klein, Paul Delmar, Nicola Voyle, Sunita Rehal, Carsten Hofmann

Alzheimers Res Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients.
Jessica Davies, Michael Martinec, Mathieu Coudert, Paul Delmar, Gracy Crane

Curr Med Res Opin· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease.
Guoqiao Wang, Scott Berry, Chengjie Xiong, Jason Hassenstab, Melanie Quintana, Paul Delmar

Stat Med· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib.
Jessica Davies, Michael Martinec, Paul Delmar, Mathieu Coudert, Walter Bordogna

J Comp Eff Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Susanne Ostrowitzki, Robert A Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Paul Delmar

Alzheimers Res Ther· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects.
David Dejardin, Paul Delmar, Charles Warne, Katie Patel, Joost van Rosmalen

Pharm Stat· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis